Troponin I test kit market seen reaching $4.52 billion by 2030

The troponin I test kit market is projected to grow from $3.22 billion in 2026 to $4.52 billion by 2030, driven by rising cardiovascular disease, faster emergency diagnostics and broader point-of-care testing. North America leads now, while Asia-Pacific is expected to grow fastest.

Why it matters: - Troponin I test kits help clinicians detect heart muscle injury quickly, which can speed diagnosis of myocardial infarction and other acute cardiac events. - The market is tied to rising cardiovascular disease, a major global health burden that is pushing demand for rapid cardiac biomarker testing. - Growth in decentralized, home-based and point-of-care testing could expand where and how cardiac diagnostics are used.

What happened: - The Business Research Company released its Troponin I Test Kit Market Report 2026, covering market size, trends and global forecasts for 2026-2035. - The market is forecast to rise from $2.95 billion in 2025 to $3.22 billion in 2026, a 9.2% CAGR. - The market is expected to reach $4.52 billion by 2030, at an 8.8% CAGR. - North America held the largest share of the market in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period.

The details: - Troponin I test kits detect and quantify cardiac troponin I levels in blood samples. - Troponin I is released into the bloodstream when heart muscle damage occurs. - The kits are used to help diagnose acute coronary syndromes and other cardiac conditions. - The technology typically uses immunoassay methods to deliver rapid results. - Growth drivers in the 2026-2030 period include AI-powered diagnostic decision support, greater demand for highly sensitive cardiac biomarkers, expansion of decentralized and home-based testing, higher emergency cardiac care spending and wider use of automated laboratory platforms. - Reported trend areas include high-sensitivity point-of-care troponin testing, AI-enhanced biomarker interpretation, ultra-rapid portable immunoassay kits, multi-biomarker panels and chemiluminescence-based automated troponin tests. - The market analysis spans Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - A free sample of the report is available here. - The full report is available here.

Between the lines: - The forecast suggests demand is shifting from basic lab testing toward faster and more automated cardiac diagnostics. - AI and multi-biomarker tools point to a market that is becoming more decision-support driven, not just more sensitive. - Regional growth patterns suggest mature adoption in North America and faster catch-up demand in Asia-Pacific. - The cited cardiovascular death toll in the U.S. underscores how persistent disease burden continues to support diagnostic spending.

What's next: - The Business Research Company expects the market to keep expanding as emergency cardiac care investment rises and automated platforms gain traction. - Competition is likely to center on faster turnaround times, higher sensitivity and portable testing formats. - Watch for broader adoption of AI-assisted interpretation and multi-biomarker panels in clinical workflows.